Know Cancer

or
forgot password

Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)


Phase 1
18 Years
N/A
Not Enrolling
Both
Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic

Thank you

Trial Information

Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)


Inclusion Criteria:



- ≥ 18 years old

- ECOG score of 0, 1, or 2

- Histologically confirmed diagnosis of non-small cell lung cancer

Exclusion Criteria:

Laboratory values demonstrating inadequate function of the following:

- Bone marrow

- Kidneys

- Liver

and

- Peripheral neuropathy Grade 2 or higher

- Greater than 2 prior chemotherapy regimens

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Dose limiting toxicities of MGd when administered concurrently with docetaxel and cisplatin

Authority:

United States: Food and Drug Administration

Study ID:

PCYC-0220

NCT ID:

NCT00102505

Start Date:

November 2004

Completion Date:

Related Keywords:

  • Non-Small-Cell Lung Carcinoma
  • Carcinoma, Bronchogenic
  • Non-Small Cell Lung Cancer
  • Lung Cancer
  • Metastatic lung cancer
  • Inoperable lung cancer
  • Advanced lung cancer
  • Large-cell lung cancer
  • Adenocarcinoma, lung
  • Squamous cell carcinoma, lung
  • Squamous cell lung cancer
  • Large cell carcinoma, lung
  • Bronchogenic
  • Carcinoma
  • Carcinoma, Bronchogenic
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
The University of Texas MD Anderson Cancer Center Houston, Texas  77030-4009